Ghent University Academic Bibliography

Show Sort by

Your filters: cql: author="CATALANO, J" or (type exact bookEditor and editor="CATALANO, J")

Add to list
- Conference Paper
- C3
FCGR3A polymorphism does not significantly affect response and outcome of follicular lymphoma patients treated in the PRIMA study with rituximab and chemotherapy followed by rituximab maintenance or observation

H Ghesquieres, J Seymour, Fritz Offner (UGent) , P Feugier, P Brice, C Haioun, O Casasnovas, J Catalano, F Jardin, L Xerri, et al.

(2011) ANNALS OF ONCOLOGY. 22(suppl. 4). p.187-188
Add to list
- Conference Paper
- C3
Rituximab maintenance for 2-years significantly improves the outcome of patients with untreated high tumor burden follicular lymphoma after response to immunochemotherapy: results of the PRIMA study

G Salles, J Catalano, P Feugier, Fritz Offner (UGent) , R Bouabdallah, D Caballero, P Brice, LM Pedersen, C Haioun, D Belada, et al.

(2010) HAEMATOLOGICA-THE HEMATOLOGY JOURNAL. 95(suppl. 2). p.229-229
Add to list
- Conference Paper
- C3
Mabthera (Rituximab) plus CVP chemotherapy for first-line treatment of stage III/IV follicular non-Hodgkin's lymphoma (NHL): Confirmed efficacy with longer follow-up

P SOLAL-CELIGNY, K IMRIE, A BELCH, KS ROBINSON, D CUNNINGHAM, A RUEDA, J CATALANO, Fritz Offner (UGent) , J WALEWSKI, J RAPOSO, et al.

(2005) BLOOD. 106(11).
Add to list
- Journal Article
- A1
CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma

R MARCUS, K IMRIE, A BELCH, D CUNNINGHAM, E FLORES, J CATALANO, P SOLAL-CELIGNY, Fritz Offner (UGent) , J WALEWSKI, J RAPOSO, et al.

(2005) BLOOD. 105(4). p.1417-1423
Add to list
- Conference Paper
- C3
An international multi-centre, randomized, open-label, phase III trial comparing rituximab added to CVP chemotherapy to CVP chemotherapy alone in untreated stage III/IV follicular non-Hodgkins lymphoma

R MARCUS, K IMRIE, A BELCH, D CUNNINGHAM, E FLORES, J CATALANO, P SOLAL-CELIGNY, Fritz Offner (UGent) , J WALEWSKI, J RAPOSO, et al.

(2003) BLOOD. 102(11).

Academic Bibliography

FCGR3A polymorphism does not significantly affect response and outcome of follicular lymphoma patients treated in the PRIMA study with rituximab and chemotherapy followed by rituximab maintenance or observation

Rituximab maintenance for 2-years significantly improves the outcome of patients with untreated high tumor burden follicular lymphoma after response to immunochemotherapy: results of the PRIMA study

Mabthera (Rituximab) plus CVP chemotherapy for first-line treatment of stage III/IV follicular non-Hodgkin's lymphoma (NHL): Confirmed efficacy with longer follow-up

CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma

An international multi-centre, randomized, open-label, phase III trial comparing rituximab added to CVP chemotherapy to CVP chemotherapy alone in untreated stage III/IV follicular non-Hodgkins lymphoma

Contents

Support

Contact